Daily BriefsIndonesia

Daily Brief Indonesia: Criterium Energy, Indofood CBP Sukses Makmur and more

In today’s briefing:

  • Criterium Energy Ltd (TSX-V: CEQ): First gas mid 3Q26. High realizations. Bulu licence extended to 2028
  • Primer: Indofood CBP Sukses Makmur (ICBP-SR SP) – May 2026


Criterium Energy Ltd (TSX-V: CEQ): First gas mid 3Q26. High realizations. Bulu licence extended to 2028

By Auctus Advisors

  • • 1Q26 production averaged 689 bbl/d, in line with prior indications.
  • Volumes are expected to be above 700 bbl/d for the remainder of the year, supported by straightforward workovers using the existing rig.
  • This is – consistent with our forecasts.

Primer: Indofood CBP Sukses Makmur (ICBP-SR SP) – May 2026

By αSK

  • Dominant Market Leader with Resilient Demand: Indofood CBP Sukses Makmur (ICBP) is a leading player in the Indonesian consumer branded products sector, holding a commanding market share of approximately 70% in the instant noodles category. Its flagship brand, Indomie, is globally recognized and enjoys strong consumer loyalty. The company’s defensive product portfolio, particularly instant noodles, demonstrates resilience during periods of weak purchasing power as it serves as an affordable meal option.
  • Strong Financial Performance and Growth Outlook: The company has a solid track record of revenue growth and profitability. Future growth is expected to be driven by Indonesia’s favorable demographics, including a large, young population and a growing middle class, which fuels domestic consumption. Strategic initiatives include continuous product innovation, with over 50 new SKUs launched in the first nine months of 2025, and international expansion, notably through the acquisition of Pinehill Company to access markets in the Middle East and Africa.
  • Key Risks and Valuation: ICBP faces risks from its dependency on imported raw materials like wheat and exposure to commodity price volatility (e.g., palm oil) and foreign currency fluctuations (IDR vs. USD). Intense competition and potential shifts in consumer preferences towards healthier options also pose threats. Despite these risks, the company’s valuation appears attractive, trading at a discount to its historical average.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars